Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 28, Issue 5, 2006, Pages 643-649

  Cattaneo, Dario ^a,b,c   Merlini, Simona ^a,b   Baldelli, Sara ^a,b   Bartolini, Barbara ^a,b   Biotechnologist, Annalisa Nicastri ^a,b   Gotti, Eliana ^a   Remuzzi, Giuseppe ^a,b   Perico, Norberto ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Center for Research on Organ Transplantation   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cyclosporine; Kidney transplantation; Mycophenolic acid; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ABDOMINAL PAIN; ADULT; ALGORITHM; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; ENTERIC COATED TABLET; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VOMITING;

ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; TABLETS, ENTERIC-COATED;

EID: 33749868376     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000245379.87563.3b     Document Type: Article

References (28)

1. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
2. Meyer MM, Munar M, Udeaja J, et al. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol. 1993;4:1306-1315.
3. Gaspari F, Caruso R, Cattaneo D, et al. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? Transplant Proc. 2001;33:3117-3119.
4. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23:100-114.
5. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation. 1996;62:1744-1752.
6. max) correlate with freedom from liver graft rejection: results of a prospective; randomized comparison of Neoral and sandimmune for liver transplantation. Transplantation. 1999;68:1839-1842.
7. Cantarovich M, Barkun JS, Tchervenkiv JI, et al. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 1998;66:1621-1627.
8. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant. 2002;2:157-166.
9. Johnston A, Kovarik JM, Mueller EA, Holt DW. Predicting patients' exposure to cyclosporin. Transplant Int. 1996;9:305S-307S.
10. 2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003;75:2086-2090.
11. Cole E, Midtvedt K, Johnston A, et al. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation. 2002;73:19S-22S.
12. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002;73:12S-18S.
13. 2 monitoring in renal transplant recipients. Nephrol Dial Transplant. 2005;20:1463-1470.
14. Cattaneo D, Gaspari F, Zenoni S, et al. Two-hours post dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy. 2005;2:95-105.
15. 2 monitoring alone. Nephrol Dial Transplant. 2005;20:1745-1747.
16. Sollinger HW. Mycophenolates in transplantation. Clin Transplant. 2004;18:485-492.
17. Budde K, Glander P, Diekmann F, et al. Reviewof the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333-1345.
18. Lindholm A. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther Drug Monit. 1995;17:631-637.
19. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet. 2000;38:427-447.
20. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs. 2001;15:279-290.
21. Baldelli S, Zenoni S, Merlini S, et al. Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. Clin Chim Acta. 2006;364:354-358.
22. Holt DW. International Cyclosporine Proficiency Testing Scheme. Available at: www.bioanalytics.co.uk; Accessed on: 2006.
23. Cantarovich M, Elstein E, de Varennes B, et al. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 1999;68:1839-1842.
24. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231-236.
25. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237-243.
26. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486.
27. Maham N, Cardella C, Cattran D, et al. Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience. Transplant Proc. 2001;33:3098-3099.
28. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant. 2002;2:148-156.